Bavarian Nordic A/S | Ownership
Companies that own Bavarian Nordic A/S
ATP Fondsmaeglerselskab A/S
2,158,683
6.68%
0
0.64%
08/23/2017
The Vanguard Group, Inc.
807,486
2.5%
3,904
0%
07/31/2018
OppenheimerFunds, Inc.
800,000
2.48%
0
0.01%
03/31/2018
Danske Bank A/S (Investment Management)
681,850
2.11%
1,256
0.13%
09/11/2018
Norges Bank Investment Management
647,630
2%
-601,137
0%
12/31/2017
Dimensional Fund Advisors LP
407,773
1.26%
64,970
0%
04/30/2018
Max Mitteregger Kapitalförvaltning AB
350,000
1.08%
350,000
2.66%
12/31/2016
BlackRock Fund Advisors
322,994
1%
1,172
0%
09/06/2018
Nykredit Bank A/S (Invt Mgmt)
161,864
0.5%
-18,217
0.07%
12/31/2017
TIAA-CREF Investment Management LLC
159,922
0.5%
-20,766
0%
03/31/2018
| Address |
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
|
|
Employees
|
- |
| Website |
http://www.bavarian-nordic.com |
| Updated |
07/08/2019 |
| Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. |
